Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium
Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County
Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…Abstract Number: 049 • 2023 Pediatric Rheumatology Symposium
What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study
Background/Purpose: Juvenile myositis (JM) patients report high rates of emotional distress but qualitative studies suggest challenges accessing high quality mental health care. We present survey…Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…Abstract Number: 042 • 2023 Pediatric Rheumatology Symposium
Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Background/Purpose: The prevalence, severity and impact of chronic pain in pediatric patients with autoimmune diseases such as childhood onset SLE (cSLE) and juvenile dermatomyositis (JDM)…Abstract Number: 056 • 2023 Pediatric Rheumatology Symposium
An Advanced Physiotherapist Practitioner Model of Care Is Ideally Suited to Address Workforce Concerns in Pediatric Rheumatology: A Retrospective Chart Review
Background/Purpose: An Advanced Physiotherapist Practitioner (APP) role was created in September 2020 at McMaster Children's Hospital, Ontario, Canada to support the growing demand for service…Abstract Number: 043 • 2023 Pediatric Rheumatology Symposium
Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)
Background/Purpose: The ChRonic nonbacterial Osteomyelitis Magnetic Resonance Imaging Scoring (CROMRIS) tool was developed to assess specific characteristics of bone and soft tissue inflammation in MRI…Abstract Number: 041 • 2023 Pediatric Rheumatology Symposium
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…Abstract Number: 044 • 2023 Pediatric Rheumatology Symposium
Validation of Newly Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis: A Virginia Cohort
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an aseptic autoinflammatory bone disease of unknown etiology. This diagnosis can be delayed due to the non-specific nature of…
- « Previous Page
- 1
- …
- 544
- 545
- 546
- 547
- 548
- …
- 2607
- Next Page »
